# US 2023/0233516 A1 · High penetration compositions and their applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0233516 A1
- Document ID: US20230233516A1
- Status: Published application
- Kind: A1
- Application number: 18/147,171
- Filed: 2022-12-28
- Published: 2023-07-27
- Earliest claimed: 2008-12-04
- Assignees: Techfields Pharma Co., Ltd.
- Applicants: Techfields Pharma Co., Ltd
- Inventors: Chongxi Yu
- Web page: https://patentgrep.com/patent/US20230233516A1

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 8/31: Hydrocarbons
- A61K 31/015: carbocyclic
- A61K 47/54: the modifying agent being an organic compound
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/16: for decreasing, blocking or antagonising the activity of the thyroid hormones
- A61P 5/34: Gestagens
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/14: Antitussive agents
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/04: for inducing labour or abortion; Uterotonics
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/18: Feminine contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 17/10: Anti-acne agents
- A61P 17/14: for baldness or alopecia
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/12: for cataracts
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/14: Ectoparasiticides, e.g. scabicides
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 15/30: Phenanthrenes
- C07C 15/38: containing four rings
- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 215/18: Halogen atoms or nitro radicals
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 295/088: to an acyclic saturated chain
- C07D 313/14: [b,f]-condensed
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 501/22: with radicals containing only hydrogen and carbon atoms, attached in position 3
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides compositions or pharmaceutical compositions of novel high penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the conditions that the parent drugs or parent drug-related compounds can. Additionally, the HPCs are capable of reaching areas that their parent drugs or parent drug-related compounds may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. For example, HPCs of NSAIA have demonstrated indications such as treating hair loss and bold. A HPC can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

A high penetration prodrug (HPP) compound of Structure L-4:
including stereoisomers and pharmaceutically acceptable salts thereof, wherein:
F4 is a structure selected from Structure F4-1, Structure F4-2, Structure F4-3, Structure F4-4, Structure F4-5, Structure F4-6, Structure F4-7, Structure F4-8, Structure F4-9, Structure F4-10, Structure F4-11, Structure F4-12, Structure F4-13, Structure F4-14, Structure F4-15, Structure F4-16, Structure F4-17, and Structure F4-18:
including stereoisomers and salts thereof;
T is selected from Structure T-1, Structure T-2, Structure T-3, Structure T-4, Structure T-5, Structure T-7, Structure T-8, Structure T-10, Structure T-11, Structure T-13, Structure T-14, and Structure T-15:
wherein each HA is independently nothing or a pharmaceutically acceptable acid selected from hydrochloride, hydrobromide, hydroiodide, nitric acid, sulfuric acid, phosphoric acid, phosphorous acid, phosphonic acid, isonicotinic acid, acetic acid, lactic acid, salicylic acid, citric acid, tartaric acid, pantothenic acid, bitartaric acid, ascorbic acid, succinic acid, maleic acid, gentisinic acid, fumaric acid, gluconic acid, glucaronic acid, saccharic acid, formic acid, benzoic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzensulfonic acid, p-toluenesulfonic acid, and pamoic acid;
L41 is selected from nothing, N, N—O, N—N(L3), N—S, N—O—CH2—O, N—S—CH2—O, N-L3, N-O-L3, N-N(L3)-L5, and L3;
L3 and L5 are each independently selected from nothing, H, —CH2COOL6, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocycloalkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted alkoxyl, substituted and unsubstituted alkylthio, substituted and unsubstituted alkylamino, substituted and unsubstituted perfluoroalkyl, and substituted and unsubstituted alkyl halide;
Y and Y1-Y14 are each independently selected from H, Cl, F, Br, I, CN, R10, CH3CC, CR6C, P(O)OR6, CF3, CF3O, CH3, CF3CF2, R5, R6, R7, R8, CF3CF2O, CH3CH2, CH3CH2CH2, (CH3)2CH, (CH3)2CHCH2, CH3CH2CH(CH3), (CH3)3C, C4H9, C5H11, CH3CO, CH3CH2CO, R5CO, CH3OC(═O), CH3CH2OC(═O), R5OC(═O), R6C(═NOR5), R6C(═NR5), CH3COO, R5COO, R5COOCH2, R6NHCOOCH2, CH3COS, CH3O, R5O, HO, R10O, CF3CH2SCH2, CHCl2, CH2COOR6, CH3S, R5S, HS, R10S, CH3OCH2CH2, R5OCH2, R10OCH2CH2, R5O(C═O), C2H5OCONH, CH2NHR8, CH3OCONH, CH3SO2, CH3SO, R5SO2, R5SO, NH2SO2, C6H5CH2, NH2, NHR10, cyclobutyl, cyclopropyl, 4-chlorophenyl, 4-fluorophenyl, CH2═CH, CH2═CHCH2, CH3CH═CH, NHR5SO2, N(R5)2SO2, R5OCH2CH2CH2, and NO2;
X, X1, X2, X3, X4, X5, and X6 are each independently selected from H, CH3, R5, CH2, CHR6, S, O, NR6, CO, CH, CR6, P(O)OR6, N, CH2═C, CH═CH, CONH, CSNH, COO, OCO, COS, COCH2, and CH2CO;
R3, R4, R5, R6, R7, and R8 are each independently selected from H, OH, Cl, F, Br, I, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, and substituted and unsubstituted heterocycloalkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted alkoxyl, substituted and unsubstituted alkylthio, substituted and unsubstituted alkylamino, substituted and unsubstituted perfluoroalkyl, and substituted and unsubstituted alkyl halide, wherein any carbon or hydrogen may be further independently replaced with O, S, N, P(O)OL7, CH═CH, C≡C, CHL7, CL5L7, aryl, heteroaryl, or cyclic groups;
L2, L8, L9, and L10 are each independently selected from nothing, —O—, —S-, -N(L3)—, N(L3)—, —N(L3)-O—, —N(L3)-N(L5)—, —N(L3)-CH2—O—, —N(L3)-CH2-N(L5)—, —O-CH2—O—, —O-CH(L3)-O—, —S-CH(L3)-O—, —O-L3-, -S-L3-, -N(L3)-L5-, and L3;
L11, L12, and L13 are each independently selected from nothing, —C(═O)—, —C(═S)—, —C(═N(L3))—,
R10 and R20 are each independently selected from nothing, H, R1, R2, R3, R4, R5, R6, R7, R8, R6CO, R6NHC(═O), R6OC(═O), —R6C(═NOR5), R6C(═NR5), R6C(═S), CNR6, and R6OC(═O)(CH2)nC(═O), R6(O═)CO(CH2)nC(═O);
R and R11-R16 are each independently selected from nothing, H, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocycloalkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted alkoxyl, substituted and unsubstituted alkylthio, substituted and unsubstituted alkylamino, substituted and unsubstituted perfluoroalkyl, and substituted and unsubstituted alkyl halide, wherein any carbon or hydrogen may be further independently replaced with O, S, P, NRs, or any other pharmaceutically acceptable groups; and
m and n are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12;
with the proviso that when T is Structure T-1, F4 is not Structure F4-1.

### Claim 27 (depends on 26)

The high penetration prodrug compound of claim 26, wherein:
F4 is a structure selected from Structure F4-2, Structure F4-4, Structure F4-5, Structure F4-6, Structure F4-7, Structure F4-8, Structure F4-9, Structure F4-10, Structure F4-11, Structure F4-12, Structure F4-13, Structure F4-14, Structure F4-15, Structure F4-16, and Structure F4-17; and
T is selected from Structure T-1, Structure T-2, Structure T-3, Structure T-4, and Structure T-5.

### Claim 28 (depends on 27)

The high penetration prodrug compound of claim 27, wherein T is Structure T-1, Structure T-2, or Structure T4.

### Claim 29 (depends on 26)

The high penetration prodrug compound of claim 26, wherein T is Structure T-1; and F4 is Structure F4-1.

### Claim 30 (depends on 26)

The high penetration prodrug compound of claim 26, which is derived from a steroid parent drug selected from progesterone, desogestrel or, ethinylestradiol, cholesterol, adrenocorticoids, and sex hormones.

### Claim 31 (depends on 26)

The high penetration prodrug compound of claim 26, which is:

### Claim 32 (depends on 26)

A pharmaceutical composition comprising a high penetration prodrug compound of claim 26, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 33 (depends on 26)

A method of treating a disease or disorder treatable by a steroid drug, comprising administering to a biological subject in need of treatment a therapeutically effective amount of a high penetration prodrug compound of claim 26, or a stereoisomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

### Claim 34 (depends on 33)

The method of claim 33, wherein the disease or disorder is selected from brain trauma, stroke, embryo implantation, early pregnancy, discoid lupus erythematosus, systemic lupus erythematosus, avoidance of pregnancy in women, multiple sclerosis, rheumatic arthritis, breast cancer, prostate cancer, and other cancers, hypoadrenalism, adrenalectomy, hypophysectomy, rheumatoid diseases, allergic manifestations, bursitis, spontaneous hypoglycemia, gout, sprue, allergy ulcerative colitis, dermatomyositis, periarteritis nodosa, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, regional ileitis, female contraceptives and abortifacients, progestin antagonists, birth control, acquired hemolytic anemia, nephrosis, cirrhotic ascites, neurodermtitis, psoriasis, pneumonia, peritonitis, typhoid fever, and meningococcemia.

### Claim 35 (depends on 33)

The method of claim 33, wherein the disease or disorder is selected from brain trauma, stroke, embryo implantation, early pregnancy, discoid lupus erythematosus, systemic lupus erythematosus, avoidance of pregnancy in women, and multiple sclerosis.

### Claim 36 (depends on 33)

The method of claim 33, wherein the prodrug compound, or a stereoisomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is applied to the biological subject by a transdermal, transmucosal, trans-nasal, trans-vaginal, trans-mouth, trans-rectal method.

### Claim 37 (depends on 33)

The method of claim 33, wherein the prodrug compound, or a stereoisomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is applied to the biological subject by a topical method.

### Claim 38 (depends on 33)

The method of claim 33, wherein the prodrug compound, or a stereoisomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is applied to the biological subject by oral, nasal, vaginal, rectal, parenteral, subcutaneous, intramuscular, intravenous, via inhalation or ophthalmic method.

### Claim 39 (depends on 33)

The method of claim 33, wherein the prodrug compound, or a stereoisomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is used at a dosage equal to or lower than 50% dosage of its parent drug to be therapeutically effective.

### Claim 40 (depends on 33)

The method of claim 33, wherein the prodrug compound, or a stereoisomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is used at a dosage equal to or lower than 25% dosage of its parent drug to be therapeutically effective.

### Claim 41 (depends on 33)

The method of claim 33, wherein the prodrug compound, or a stereoisomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is used at a dosage equal to or lower than 10% dosage of its parent drug to be therapeutically effective.

### Claim 42 (depends on 33)

The method of claim 33, wherein the prodrug compound, or a stereoisomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is used at a dosage equal to or lower than 5% dosage of its parent drug to be therapeutically effective.

### Claim 43 (depends on 33)

The method of claim 33, wherein the prodrug compound, or a stereoisomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is used at a dosage equal to or lower than 2% dosage of its parent drug to be therapeutically effective.

### Claim 44 (depends on 33)

The method of claim 33, wherein the prodrug compound, or a stereoisomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is used at a dosage equal to or lower than 1% dosage of its parent drug to be therapeutically effective.

### Claim 45 (depends on 33)

The method of claim 33, wherein the prodrug compound, or a stereoisomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is used at a dosage equal to or lower than 0.1% dosage of its parent drug to be therapeutically effective.
